We recommend that aducanumab and lecanemab, which have received accelerated approval from the US FDA for the treatment of AD [16,17], donanemab [19], and Relyvrio (Cinpanemab) for ALS [21,22] can be good targets to investigate their transferrin conjugates expressed by mRNA as a logical option to rejuvenate their status and frontline ND treatment. Here, TF is linked to amyotrophic lateral sclerosis.